INTRODUCTION: As the prevalence of cigarette smoking has declined, the proportion of smokers who smoke less than 10 cigarettes/day (cpd) has increased. Varenicline may provide an effective pharmacotherapeutic treatment option for increasing smoking abstinence rates among light smokers. METHODS: We conducted a randomized, placebo-controlled clinical trial evaluating the efficacy of varenicline for increasing smoking abstinence rates among light smokers (5-10 cpd). Participants received varenicline or placebo for 12 weeks. Outcomes were assessed at 3 and 6 months. RESULTS:Ninety-three participants were randomized. Fifty-two percent of participants terminated the study early. At end-of-treatment (3 months), the point prevalence smoking abstinence rate was 53.3% in the varenicline group compared to 14.5% in placebo (odds ratio [OR]: 6.69, 95% confidence interval [CI]: 2.48-18.06, P < .001), and the prolonged smoking abstinence rate was 40.0% and 8.3%, respectively (OR: 7.33, 95% CI: 2.24-23.98, P = .001). At end-of-study (6 months), the point prevalence smoking abstinence rate was 40.0% in the varenicline group compared to 20.8% in placebo (OR: 2.53, 95% CI: 1.01-6.34, P = .047), and the prolonged smoking abstinence rate was 31.1% and 8.3%, respectively (OR: 4.97, 95% CI: 1.49-16.53, P = .009). The estimated magnitude of the treatment effect remained consistent across the various missing data assumptions and in analyses that adjusted for gender. Nausea and sleep disturbance were more commonly reported in the varenicline group. CONCLUSIONS:Varenicline was safe and effective for increasing long-term smoking abstinence rates in a population of predominantly White light cigarette smoker. The efficacy of varenicline in this study was comparable to that observed in heavier smokers. IMPLICATIONS: Our findings demonstrate that varenicline is effective for increasing smoking cessation in light smokers. Our findings have implications for advancing the treatment of light smokers in clinical practice.
RCT Entities:
INTRODUCTION: As the prevalence of cigarette smoking has declined, the proportion of smokers who smoke less than 10 cigarettes/day (cpd) has increased. Varenicline may provide an effective pharmacotherapeutic treatment option for increasing smoking abstinence rates among light smokers. METHODS: We conducted a randomized, placebo-controlled clinical trial evaluating the efficacy of varenicline for increasing smoking abstinence rates among light smokers (5-10 cpd). Participants received varenicline or placebo for 12 weeks. Outcomes were assessed at 3 and 6 months. RESULTS: Ninety-three participants were randomized. Fifty-two percent of participants terminated the study early. At end-of-treatment (3 months), the point prevalence smoking abstinence rate was 53.3% in the varenicline group compared to 14.5% in placebo (odds ratio [OR]: 6.69, 95% confidence interval [CI]: 2.48-18.06, P < .001), and the prolonged smoking abstinence rate was 40.0% and 8.3%, respectively (OR: 7.33, 95% CI: 2.24-23.98, P = .001). At end-of-study (6 months), the point prevalence smoking abstinence rate was 40.0% in the varenicline group compared to 20.8% in placebo (OR: 2.53, 95% CI: 1.01-6.34, P = .047), and the prolonged smoking abstinence rate was 31.1% and 8.3%, respectively (OR: 4.97, 95% CI: 1.49-16.53, P = .009). The estimated magnitude of the treatment effect remained consistent across the various missing data assumptions and in analyses that adjusted for gender. Nausea and sleep disturbance were more commonly reported in the varenicline group. CONCLUSIONS:Varenicline was safe and effective for increasing long-term smoking abstinence rates in a population of predominantly White light cigarette smoker. The efficacy of varenicline in this study was comparable to that observed in heavier smokers. IMPLICATIONS: Our findings demonstrate that varenicline is effective for increasing smoking cessation in light smokers. Our findings have implications for advancing the treatment of light smokers in clinical practice.
Authors: Kolawole S Okuyemi; Kari Jo Harris; Monica Scheibmeir; Won S Choi; Joshua Powell; Jasjit S Ahluwalia Journal: Nicotine Tob Res Date: 2002 Impact factor: 4.244
Authors: Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia Journal: J Natl Cancer Inst Date: 2012-01-25 Impact factor: 13.506
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Lorraine R Reitzel; Tracy J Costello; Carlos A Mazas; Jennifer I Vidrine; Michael S Businelle; Darla E Kendzor; Yisheng Li; Ludmila Cofta-Woerpel; David W Wetter Journal: Nicotine Tob Res Date: 2009-02-26 Impact factor: 4.244
Authors: Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Babalola Faseru; Allen Greiner; Edward F Ellerbeck; Ron Krebill; Rachel F Tyndale; Neal L Benowitz; Jasjit S Ahluwalia Journal: JAMA Date: 2022-06-14 Impact factor: 157.335
Authors: Sarah E Maggio; Meredith A Saunders; Thomas A Baxter; Kimberly Nixon; Mark A Prendergast; Guangrong Zheng; Peter Crooks; Linda P Dwoskin; Rachel D Slack; Amy H Newman; Richard L Bell; Michael T Bardo Journal: Psychopharmacology (Berl) Date: 2018-02-18 Impact factor: 4.530
Authors: Sarah E Maggio; Meredith A Saunders; Kimberly Nixon; Mark A Prendergast; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Richard L Bell; Michael T Bardo Journal: Drug Alcohol Depend Date: 2018-10-17 Impact factor: 4.492
Authors: Jeremy E Drehmer; Man Luo; Emara Nabi-Burza; Bethany Hipple Walters; Jonathan P Winickoff Journal: Acad Pediatr Date: 2020-10-07 Impact factor: 3.107